Abstract

CHROMATOGRAPHIC REVIEW: DPP-4 INHIBITORS INCLUDE: LINAGLIPTIN, SITAGLIPTIN, VIDAGLIPTIN, AND SAXAGLIPTIN

Jatin Sharad Patil*, Amitkumar R. Dhankani and Dr. Sunil P. Pawar

Abstract

The frequency of type 2 diabetes mellitus (DM), a chronic metabolic condition, has been rising gradually worldwide. GLP-1 and GIP mediate the effect of the more recent family of oral hypoglycemic drugs known as dipeptidyl-peptidase-4 (DPP-4) inhibitors. DPP-4 inhibitors, such as linagliptin, sitagliptin, vidagliptin, and saxagliptin, treat type 2 diabetes. The analytical method for determining linagliptin, sitagliptin, vidagliptin, and saxagliptin in pharmaceutical formulations, both alone and in combination with other medications, was revealed by examining the literature. In this comprehensive study, the comparison of thirty-seven analytical methods—including HPLC and bioanalytical techniques is most clearly demonstrated. Analytical development must be tested to produce reliable results for regulatory filings. The invention of drugs ushered in a revolution in human health.

Keywords: Linagliptin; Sitagliptin; Vidagliptin; Saxagliptin; Review Article.